Ovation Pharmaceuticals

Ovation Pharmaceuticals is a pharmaceutical company based in the United States. It was established in 2000 and has since been involved in the development, manufacturing, and marketing of pharmaceutical products, with a focus on niche markets and underserved patient populations.

History

Ovation Pharmaceuticals was founded in 2000 by Jeffrey S. Aronin. The company was initially focused on acquiring and revitalizing neglected drugs in the pharmaceutical industry. In 2009, it was acquired by Lundbeck, a global pharmaceutical company based in Denmark, for $900 million. This acquisition expanded Lundbeck's portfolio and presence in the U.S. market.

Business Model

Ovation Pharmaceuticals' business model is centered on the acquisition and commercialization of pharmaceutical products that are not the primary focus of large pharmaceutical companies. This includes drugs for rare diseases and conditions that affect a small percentage of the population. The company's strategy involves identifying these overlooked products, acquiring the rights, and then investing in their development and marketing.

Products

Over the years, Ovation Pharmaceuticals has built a diverse portfolio of products. These include drugs for neurology, cardiology, and endocrinology. Some of its notable products include Xenazine for the treatment of Huntington's disease, Sabril for the treatment of epilepsy, and Cystagon for the treatment of cystinosis.

Impact

Ovation Pharmaceuticals has had a significant impact on the pharmaceutical industry, particularly in the area of rare diseases. By focusing on neglected drugs, the company has been able to bring important treatments to market for patients who previously had few or no options.

   This article is a pharmacology-related stub. You can help WikiMD by expanding it!